HOTH THERAPEUTICS INC (HOTH)

US44148G2049 - Common Stock

0.81  +0.04 (+5.21%)

Premarket: 0.78 -0.03 (-3.7%)

HOTH THERAPEUTICS INC

NASDAQ:HOTH (12/20/2024, 8:17:00 PM)

Premarket: 0.78 -0.03 (-3.7%)

0.81

+0.04 (+5.21%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%48.33%
Sales Q2Q%N/A
CRS11.6
6 Month-12.34%
Overview
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Ins Owners0.93%
Inst Owners5.05%
Market Cap5.59M
Shares6.90M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82.5
Short Float %6.7%
Short Ratio0.38
IPO02-15 2019-02-15
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

HOTH Daily chart

Company Profile

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The firm also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.

Company Info

HOTH THERAPEUTICS INC

590 Madison Avenue, 21St Floor

New York City NEW YORK 10020

P: 16467562997

CEO: Robb Knie

Employees: 3

Website: https://hoththerapeutics.com/

HOTH News

News Imagea month ago - Hoth Therapeutics, Inc.Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that the Company's Board of Directors...

News Image2 months ago - Hoth Therapeutics, Inc.Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet...

News Image2 months ago - Hoth Therapeutics, Inc.Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to...

News Image3 months ago - Hoth Therapeutics, Inc.Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today...

News Image4 months ago - Hoth Therapeutics, Inc.Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional...

News Image4 months ago - Hoth Therapeutics, Inc.Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Cancer Patient Ceased Treatment After One Week Due to Rapid Success In the reported case, the patient, a 59-year-old female undergoing treatment at George...

HOTH Twits

Here you can normally see the latest stock twits on HOTH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example